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ABSTRACT
Corticosteroids are an often prescribed anti-inflammatory medication.
They are used to treat disease processes of every system of the body. Those
disease processes or procedures for which corticosteroids are often prescribed
are cancer, bone marrow transplants, collagenous diseases (systemic lupus
erythematosus), rheumatoid arthritis, leukemia, and anemia.
However, despite the therapeutic benefits of corticosteroids, many
adverse effects are possible. Gastrointestinal difficulties, steroid myopathy,
hyperglycemia, osteoporosis, impaired cellular immunity, decreased
neuropsychological functioning, and avascular necrosis are just a few of the
possible adverse effects.
Patients receiving corticosteroids will often be seen by physical therapists
for either their primary or secondary diagnoses. Physical therapists are not
often instructed in the possible adverse effects of corticosteroids that may occur.
The purpose of this study was to create an increased awareness for health
professionals (specifically physical therapists) concerning the possible adverse
effects of corticosteroids and how these adverse effects may influence patient
evaluation, treatment, and progression. A review of the literature was done.
The adverse effects covered were avascular necrosis, osteoporosis, impaired
ix

cellular immunity, GI disturbances, neuropsychological difficulties, and steroid
myopathy. For each of the selected adverse effects, the physiologic mechanism,
clinical research, and therapeutic intervention were discussed. Finally,
precautions or suggestions for the physical therapist relative to working with the
patient on corticosteroids was offered.

x

CHAPTER I
INTRODUCTION
The definition of a physical therapist is someone who is "... responsible
for evaluating, planning, conducting, and supervising a physical therapy program
••• 111(P1S0S)

Many factors may exist that will alter the evaluation, treatment

choices, and progression of a patient's rehabilitation. Medication is one of those
factors.
One powerful category of medication is corticosteroids (CS). The most
common corticosteroids are cortisone, hydrocortisone, dexamethasone,
methylprednisolone, prednisolone, and prednisone. 2 ,3,4 These generic names
may be marketed under many trade names.
Corticosteroids are prescribed for their strong anti-inflammatory
properties and chemotherapeutic qualities. Corticosteroids produce their effects
on the body by Circulating in the blood, passing through the cell membrane, and
attaching to intracellular receptors. s Corticosteroids exhibit anti-inflammatory
qualities because they can alter the function of cells involved in the inflammatory
process. These cells include macrophages, neutrophils, eosinophils, basophils,
endothelial cells, fibroblasts, prostaglandins, and lymphocytes. On the other
hand, chemotherapeutic qualities of CS are used to treat hematologic
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malignancies and malignant lymphomas as well as malignant tumors.2 CS are
also used to decrease cerebral edema or cord compression when cancer
metastasizes to the CNS or spinal cord injury occurs.2 Corticosteroid (CS)
receptors exist not only in the cells involved with the inflammatory process but
also in most cells of the body; i.e., skeletal muscle. Skeletal muscle is
considered a target organ for CS and steroid use often results in CS induced
weakness, which is also known as steroid myopathy.
Because of the therapeutic benefits of CS, many patients will receive
them for either the primary and/or secondary diagnoses of any system of the
body. The major areas for which CS are prescribed are respiratory diseases,
allergies, hematologic disorders, collagenous diseases, disorders of the GI
system, metabolic and endocrine disorders, hematological disorders,
neuromuscular, cardiovascular, renal disorders, and cancer. 6 The most common
disease processes for which CS are used are: 1) asthma, 2) rheumatoid
arthritis, 3) ulcerative colitis, 4) Crohn's disease, 5) systemic lupus
erythematosus (SLE), and 6) cancer. 2,7-9 They are also used after any organ,
tissue, or bone marrow transplant as one of the many anti rejection drugs these
patients will have to take for the rest of their Iives. 2
Despite the therapeutic benefits of CS in these patient populations, a
wide range of adverse effects also exist. In addition, just as CS are used to treat
disorders/diseases of all systems of the body, the adverse effects may manifest
in one or more systems of the body. A review of the literature has produced a
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lengthy list of potential adverse effects. 2•3 •5 •7 Hypertension, GI complications,
avascular necrosis, osteoporosis, electrolyte imbalances, glucose intolerance,
myopathy, impaired cellular immunity, atherosclerosis, hyperglycemia, and
neuropsychological difficulties are the most commonly agreed upon adverse
effects of CS.

It is also important to note that not every patient receiving CS will

develop any of these adverse effects.
The adverse effects of CS may influence a physical therapist's approach
to evaluation, treatment, and progression of a patient's rehabilitation program.
That is why knowledge of the adverse effects of CS is important for physical
therapists and other medical personnel. The adverse effects most pertinent to
physical therapy are osteoporosis, gastrointestinal complications, avascular
necrosis, reduced cellular immunity, myopathy, and neuropsychological
difficulties.
Thus, the purpose of this study is to create an increased awareness for
health professionals (specifically physical therapists) concerning the possible
adverse effects of CS and how these adverse effects may influence patient
evaluation, treatment, and progression. The adverse effects mentioned in the
above paragraph are discussed. The physiologic mechanism, clinical research,
and therapeutic intervention are presented for each effect as well as precautions
or suggestions for the physical therapist relative to working with patients
receiving CS.

CHAPTER II
OSTEOPOROSIS
Osteoporosis is probably one of the most recognized adverse effects of
long-term corticosteroid (CS) use. A study by Grecu, Weinshelbaum, and
Simmons10 concluded that most bone density is lost within one year after
initiating CS therapy. Within that first year bone density may decrease by 4-

10%. After the first year, bone loss most likely still occurs but at a much lesser
extent.
Mechanism
One mechanism by which CS may induce osteoporosis is fairly well
described in today's Iiterature. 2 Another possible mechanism is briefly
mentioned. s.11 The mechanism well described in literature begins with
corticosteroids inducing hypocalcemia. Because the body becomes
hypocalcemic, it will leach calcium from the skeletal system to meet its
requirements, leading to a reduction in bone density and eventually leading to
osteoporosis. "Steroids cause bone loss by decreasing intestinal calcium
absorption and by increasing urinary calcium excretion by the kidney.
Decreased blood calcium results in mild hyperparathyroidism, which in turn
accelerates bone resorption."s(P1206) Basically there is an imbalance between
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bone destruction and bone formation. The other possible physiologic
mechanism that may lead to osteoporosis is a reduced level of sex hormones
which may increase bone resorption. s,11 CS decrease the level of sex hormones
in the body by altering gonadal function and the amount of sex hormones
produced by the ovaries and testes. 11
Clinical Research
Most authors agree that osteoporosis is an adverse effect of CS therapy.
The limitation of some studies is that it is difficult to separate the effects of age
related osteoporosis versus the effects of corticosteroids; age and
corticosteroids most likely have an additive effect relative to osteoporosis.
When bone density decreases, it puts the patient at a higher risk for
fractures. Bone density in trabecular bone (such as that of the vertebrae) seems
to be affected by CS more than is cortical bone. Boumpas et al s compared
trabecular and cortical bone densities in those receiving long-term CS versus
those receiving intermittent CS therapy. Neither therapeutic intervention had a
significant effect on cortical bone densities and only long-term CS therapy had a
negative effect on trabecular bone.
A study by Troiano, Jatkowitz, Cook, Basil, and Zito 12 found that the
incidence of fractures was higher while the patient was receiving CS as
compared to the incidence for an equal time period before initiation of CS
therapy. The medical records of 103 patients with Multiple Sclerosis receiving
CS were reviewed. The study reviewed variables such as length of treatment,
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cumulative dose of CS, rate of fractures, and the location of fractures. The rate
of fractures were as follows: "Overall, 26 (25%) of the patients had had a total of
30 fractures. Twenty (19%) of the patients had 23 fractures after starting steroid
therapy and six (6%) of the patients had seven fractures in an equivalent period
of time preceding the initiation of steroid therapy.,,12(P1389) Most fractures were
associated with falls, but some were precipitated by less traumatic events, such
as turning in bed; in one case a spontaneous fracture was reported.
Although many patients may have no option except to remain on
corticosteroids, other medications have been used prophylactically to ward off
osteoporosis and the increased risk of fractures.
Therapeutic Intervention
ProphylactiC medications which have been used with moderate results
are 11-13 calcitrol, calcitonin, and biphosphates. The use of intermittent cyclic
therapy (ICT) etidronate is fairly new. A study by Adachi et al 11 compared the
bone mineral density (BMD) in the lumbar spine of 68 patients being treated with
corticosteroids. Thirty-five of those patients were treated prophylactically with
ICT etidronate and the control group of 33 received no prophylactic treatment.
Bone mineral density was again tested in one year. In the ICT etidronate group,
the BMD had increased by 3.82% as compared to a 1.78% decrease in the
control group.
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Precautions for the Physical Therapist
Because CS are used in many patient populations, physical therapists
need to be aware that patients receiving long-term CS may be osteoporotic and
special attention must be given while assessing the patient and designing a
treatment program. For example, when manual muscle testing (MMT), the
shortest lever arm possible should be used to reduce the amount of torque on
the skeletal system (especially the long bones of the humerus and femur).
Options for strengthening include using pool therapy and closed chain exercises
to reduce the shearing forces on the bones. 2 If the patient is unsteady, the use
of an assistive device to help prevent falls is indicated. One of the most
important things to do for the patients is to educate them in proper body
mechanics during activities of daily living (ADLs).

CHAPTER III
COMPROMISED IMMUNITY
For those receiving CS, a compromised immune system is another
adverse effect. Corticosteroids weaken the immune system by decreasing the
local inflammatory response which may cause the infection to spread. 14 Many of
the disease processes that require treatment with corticosteroids may have
already put the body and the immune system in a weakened state. The
combination of the disease process at hand and the steroid-induced
immunosuppression can be a fatal combination.
Mechanism
The mechanism by which CS suppress the immune system is fairly well
understood but also complex. One explanation begins with the depression of
lymphocytes and monocytes 15 which occurs four to six hours following the
administration of CS. Boumpas et al 5 summarize what occurs at the cellular
level: "glucocorticoids inhibit the access of leukocytes in inflammatory sites;
interfere with the functions of leukocytes, endothelial cells, and fibroblasts; and
suppress the production and effects of humoral factors involved in the
inflammatory response."(P1198) In a sense, corticosteroids bind well to sites of
inflammation and do not allow the leukocytes, fibroblasts, etc. to invade the site
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and fight off the infection. Several studies exist that conclude that CS put the
patient at a higher risk for acquiring infections. 2•5 •15
Clinical Research
A meta analysis of 71 trials involving 2000 CS treated patients concluded
that the relative risk for infection was approximately two times that of controls. 5
Dowell and Bresee 15 came to a similar conclusion. In their 1993 study, they
concluded that the use of CS multiplies the risk (incidence) of severe varicella or
"chicken pox." They studied 35 children who were suffering from severe
varicella and 10,000 control subjects. The purpose of their study was to
determine if there is a correlation between CS use and severe varicella. Sixteen
of the 35 children in the experimental group had been exposed to some form of
CS, whereas in the control group, only 20 out of the 10,000 subjects had been
exposed to CS. The dosages of corticosteroids in the experimental group
ranged from .5-2.5 mg\kg\d. Among the experimental group, four of the 16
exposed to CS succumbed to the severe varicella. Dowell and Bresee 15
concluded ''the odds of steroid use in otherwise immunocompetent children who
contracted severe varicella was 178 times higher than in the general
population. n(p225)
Dowell and Bresee 15 identified three limitations in their study. One
limitation was the small number of subjects. Secondly, they may have
overestimated the odds ratio. Finally, a third factor may exist that ties together
the risk of severe varicella and the use of steroids. Regardless of the limitations
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of the study, the authors still feel that steroid immunosuppression should be a
concern among doctors and those receiving CS.
Therapeutic Intervention
In the review of the literature, no information was found on any substance
that could be used to decrease the likliehood of steroid induced
immunosuppression.
Precautions for the Physical Therapist
Physical therapists will often treat patients who are immunosuppressed by
CS. There are many ways to protect the patient. The single most effective way
to prevent the spread of infections is proper hand-washing techniques for the
physical therapist and the patient. 2 Jennifer Grant2 of John Hopkins Hospital
states, "it is encouraged that patients with a white blood cell (WBC) count of less
than 1000 mm 3 or a neutrophil count of less than 5000 mm 3 should wear a
protective mask.,,(p58) Physical therapists should be responsible for using
universal precautions and gowning and gloving when appropriate. The patient
should be educated to avoid public areas where many people congregate as the
possibilities of contracting an unwanted infection abound.

CHAPTER IV
GI COMPLICATIONS
Gastrointestinal complications often occur in those taking CS. The most
common complications are perforation of peptic ulcers and perforation of colonic
diverticula.
Mechanism
For perforation of both peptic ulcer and colonic diverticula, there are
separate possible mechanisms of injury. Three primary explanations of how CS
may cause peptic ulcer perforation exist. Alexander, Schuman, and Vetto's 16
stated mechanism of peptic ulcer perforation is by "lymphoid depletion in the
colonic lymphoid patches, resulting in bacterial invasion and subsequent
perforation." As discussed previously, CS leave the patient in an
immunosuppressed condition, which decreases the leukocyte counts and leave
the patient less able to fight off the bacteria that enter the GI tract. Finally,
corticosteroids are also thought to decrease the turnover of the mucosal cells
lining the GI tract leaving the lining of the GI tract susceptible to infection and
subsequent perforation.
A second complication is perforation of colonic diverticula. Arsura 17
believes areas of the colon are repetitively traumatized by fecal material. If
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mucosal regeneration is slowed by CS, bacteria have a chance to invade the
lining of the colon and eventually cause perforation. 17-18 Because of CS induced
immunosuppression, the patient is in a more vulnerable state for bacterial
invasion. 17•18
Clinical Research
There are many studies identifying a statistically significant correlation
between CS use and perforation of ulcers and colonic diverticula of the GI tract.
One study used 71 controlled trials. Subjects were randomly assigned to Group
1 or 2. Group 1 received CS, Group 2 received non-steroidal treatment.
Subjects were treated for four days. The incidence of peptic ulcers was 1.8% in
Group 1 and 0.8% in Group 2.4
Warshaw, Welch, and Ottinger18 strongly suggested that CS may cause
perforation of the colon. Their quasi experimental study included 13 subjects
whose average duration on steroids was 3.4 years. All subjects were receiving
CS for diseases other than that of the bowel. Surgery to repair a perforated
colon was needed in 10 of the 13 cases. In five cases, the areas of perforation
were close to areas of diverticula, but in the other eight cases, the perforations
were in unusual areas. Of the eight cases that were unusual, five had punched
out perforations, which are not normally seen. One subject had perforations at
the rectosigmoid colon. Other unusual findings were perforations of the
transverse and descending colon and areas of gangrene. The authors felt that
because of the uniqueness of the perforations and the fact that the patients were
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being treated for diseases other than that of the GI tract, the CS therapy most
likely contributed to the perforation in these patients.
Dayton, Kleckner, Dennistoun, and 8rown's3 study evaluated (1) the
incidence of steroid-related ulcer perforation and (2) the clinical problems and
prognosis of patients with this complication. They did retrospective chart
reviews of 151 patients with peptic ulcer perforation. Twenty-five (17%) of the
subjects had received CS within one week of perforation. The authors agree
that this incidence is similar to the findings of other studies and is slightly higher
than the 5% to 10% incidence of peptic ulcer perforation found in the general
population. Therefore, if the patient is receiving CS, he/she has a greater
chance of peptic ulcer perforation than if he/she was not taking CS. The
prognosis for patients was poor. There was an 85% mortality rate for those over
50 years of age and 17% for those under 50 years of age. The authors
concluded that CS therapy causes a significant number of all perforations and
there is a high mortality for these patients.
Diethelm 14 also concluded that "steroid ulceration" is a complication that
may occur in 10% to 30% of those on CS for more than one month. He also
reported that the dosage levels of cortisone and prednisone may be associated
with an increased incidence of ulceration. Daily dosage levels greater than 50
mg/d of cortisone and 20 mg/d of prednisone appear to be associated with an
increased risk of ulceration.
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Carson et al 19 disagreed with these conclusions. The authors found the
overall risk of GI complications in users of CS to be 2.8 per 10,000 personmonths. They concluded that the rate of GI complications did not warrant the
use of prophylactic medication.
Therapeutic Intervention
Perforation of the GI tract often ends in surgical intervention. Prior to
perforation, however, prophylactic medications may ward off steroid-induced
complications.
Antacids and H2 blockers have been used with moderate success to
guard against ulcer formation 14 and the use of ranitidine has also been
suggested. 20 Seale and Compton 4 disagree with the prophylactic use of
medications, such as antacids and H2 blockers, as their use is not warranted. 4
Precautions for the Physical Therapist
As physical therapists, recognizing the signs and symptoms of ulceration
and/or perforation would facilitate immediate referral to a physician. Signs and
symptoms may include 1) pain which is burning, gnawing, or aching,
2) soreness, 3) an empty feeling, or 4) hunger. 21 Pain is usually unrelenting and
may range from mild to severe. Pain may be lessened by the use of dairy
products, antacids, or H2 blockers.

CHAPTER V
AVASCULAR NECROSIS
Avascular necrosis (AVN) is a recognized adverse effect of CS
therapy.22-26 Four common features of corticosteroid-induced AVN exist. 27 First,
no known trauma is implicated. Second, no other underlying cause of
nontraumatic avascular necrosis is found. Third, the patient has been receiving
corticosteroids for an extended period of time and in excess of physiological
requirements. Last of all, the disease process for which the patient is receiving
CS does not cause AVN.
AVN most commonly occurs in the hip joint. 24 The knee, ankle, shoulder,
elbow, and wrist have also been implicated. 14 When avascular necrosis affects
the femoral head, total hip arthroplasty is the most common surgical intervention.
The specific cause of steroid-induced avascular necrosis is not known, but a few
causes have been hypothesized.
Mechanism
Wang, Sweet, Reger, and Thompson 28 proposed three possible
mechanisms of steroid-induced AVN. The first theory is that the blood hypercoagulates and there is subsequent vascular insufficiency to the femoral head.
The second possible cause of AVN is osteoporosis which may eventually lead to
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fracture and collapse of the femoral head. The last mechanism of AVN may be a
result of hyperlipidemia. The alteration of fat metabolism by CS may cause the
liver to become excessively fatty and cause the liver to release small fat emboli.
These small fat emboli may impair the circulation of the femoral head, causing
bone death and resultant AVN. This latter theory appears to be the most
popular school of thought.3.22.24.25.27.28
A study by Fisher et al 22 supports this theory. Fisher studied 66 New
Zealand rabbits. The 66 rabbits were split into two experimental groups and one
control group. Two experimental groups of 30 subjects each were formed. The
only difference between the groups was that they received slightly different
corticosteroids. The six remaining rabbits made up the control group. The
rabbits in the experimental group received dosages of CS in excess of
physiological requirements. Five rabbits in each experimental groups and one
from the control group were killed each month for six months. Histological and
general autopsies were done. The results indicated that high doses of CS cause
hyperlipidemia and an excessively fatty liver. The reason for hyperlipidemia is
not well understood. One theory states that CS cause lipid mobilization in the
adipose tissue. The increased lipid mobilization causes the liver to become so
full of fat that the cells eventually burst. Fat emboli enter the bloodstream via
the hepatic circulation. Through the hepatic circulation, the emboli enter the
circulatory system of the heart and lungs and are transported to the periphery of
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the circulatory system. Fisher and associates found fat emboli in subchondral
bone of the rabbits and areas of osteocytic death after three to five months.
Clinical Research
Alarcon and associates26 describe an atypical case of a 48-year-old
woman who developed AVN of the femoral head after long-term corticosteroid
use. She was receiving corticosteroids for "feigned" bronchial asthma.
"Feigned" bronchial asthma is considered a factitious disorder. "Factitious
disorders are characterized by physical and/or psychological symptoms that are
intentionally produced or feigned.,,26(P139) In 1990, the woman was evaluated for
refractory asthma. She stated she had had asthma since she was 13 years old
but her asthma did not become severe enough to elicit the use of CS until she
was 37 years old. She used parenteral, oral and inhaled corticosteroids. Her
history and physical revealed that she had undergone 11 knee surgeries, two of
which were total knee arthroplasties. At the time of the evaluation, she relied on
a wheelchair for locomotion secondary to the condition of her knees. She had a
host of other problems and was receiving nine different medications. At the time
of her evaluation, chest X-rays were unremarkable as were the results of her
pulmonary function tests. In 1990 and again in June 1991, she was advised to
decrease the use of her CS. She was lost to follow up until March 1992 when
she presented with left hip pain. The diagnosis of AVN was made.
Conservative treatment with core decompression was done, but in June 1992,
she required a total hip arthroplasty (THA). During this hospitalization time, she
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did agree to taper her CS dosage. At discharge she was taking only 8 mg of
prednisone every other day and eventually was able to taper it to 5 mg every
other day. Alarcon and associates stated that no cause of AVN, other than CS
could be shown.
Not only is AVN implicated in long-term corticosteroid use, such as in the
above case, but is also infrequently noted in short-term CS use. Anderton, Orth,
and Helm 25 reported the case study of a 27-year-old male whom after a sevenday course of dexamethasone for increased intercranial pressure presented with
avascular necrosis of both humeral heads and femoral heads. The man was first
seen for complaints of shoulder pain that had persisted for one year. No history
of trauma to the shoulders was present. Two years prior to the onset of
symptoms the patient had been treated with oral dexamethasone for increased
intercranial pressure. No definitive diagnosis was given for the increased
intercranial pressure. He received 4 mg of dexamethasone every six hours for
seven days. Complete recovery was achieved. At the time of evaluation, three
years after receiving the dexamethasone, range of motion (ROM) in both
shoulders was compromised. X-rays showed marked AVN of bilateral shoulders
and moderate involvement at both hips. Other possible causes of AVN from
disease processes or systemic involvement were ruled out. Anderton et al
concluded that even a short duration of CS does not rule out the possibility of
AVN.
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Fisher and Bickel 27 along with help of Patterson and company reviewed
77 cases of non-traumatic avascular necrosis at the Mayo Clinic.

Patient

histories were reviewed and prescriptions for CS were noted. Prednisone was
the most common drug prescribed. Every case except one was receiving
dosages in physiological excess. Of the 77 subjects, 23 were receiving CS for
collagen-vascular difficulties, 16 for dermatological problems, 5 for hematologic
problems, 7 for gout, 5 for pulmonary disease, and 21 for miscellaneous
diseases. The time period between the onset of symptoms and diagnosis of
AVN, via X-rays, was determined. The average time between initiation of CS
treatment and onset of symptoms was nine months. All cases had the classic
signs of corticosteroid-induced AVN.
Therapeutic Intervention
In the review of the literature, no reference was made to any prophylactic
medications that offset the chance of AVN in patients receiving corticosteroids.
Intervention normally occurs only after the diagnosis of AVN has been made. By
the time AVN is diagnosed, it has usually progressed so far that surgical
intervention is needed. 2 ,18,26,27 With avascular necrosis of the femoral head, total
hip arthroplasty (THA) is the intervention of choice. 14 Total hip arthroplasty
allows the patient to be free of pain and improve his/her ambulatory skills.
A fairly new conservative treatment of AVN of the femoral head is showing
promise as an option to THAs. The new procedure involves using a
vascularized fibular graft. 23 Malizos and associates salvaged 10 hips of eight
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patients using a vascularized fibular graft. All patients experienced relief of pain
following surgery. Patients utilized a pair of crutches for six months and
advanced to one crutch for three more months. Not one of the patients needed
any additional hip surgeries in the two-year follow-up of this study.
Precautions for the Physical Therapist
Once a patient is diagnosed with AVN, little to nothing can be done to
prevent the progression of AVN. A conservative way to alleviate pain is the use
of a cane. Another way to alleviate pain and prevent further collapse of the bone
is to exercise the surrounding joint musculature in a non-weight bearing
position. 2 However, this conservative treatment will most likely not provide
enough relief for the patient and surgical intervention will be needed.
As a physical therapist, knowing the signs and symptoms of AVN will
allow for differential diagnosis and referral to a physician. 29 Pain is the major
patient complaint. The pain is localized to the joint and the patient will usually
complain of stiffness. Upon palpation, the patient may complain of tenderness
and the joint may be swollen. Restricted range of motion will be noted.

CHAPTER VI
NEUROPSYCHOLOGICAL DIFFICULTIES
Many neuropsychological symptoms have presented in patients receiving
corticosteroids. The most common neuropsychological side effects of CS in
adults are euphoria, depression, and psychotic reactions characterized by
delusion, hallucination, stupor, and catatonia. 30 The most common
neuropsychological side effects in children are affective changes, insomnia,
restlessness, depression, reduced verbal memory, increased irritability, and
fatigue. 31 The effects of CS on neuropsychological functioning are variable. In
the systemic lupus erythematosus (SLE) patient population, CS have been found
to improve cognition, mood, and symptom rating. 32 The intensity of
psychological changes may depend on dosage, sensitivity of the patient, and the
patient's underlying personality.2
Mechanism
In the review of the literature, no explanation for the alteration in an
adult's neuropsychological functioning was offered. For children, one
hypothesis has been stated. 33 Corticosteroids suppress the formation of
adrenocorticotropic hormone (ACTH), a naturally occurring hormone in the body.
Naturally occurring glucocorticosteroids are said to facilitate brain maturation.
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With the use of oral, parenteral, or inhaled corticosteroids, ACTH production is
suppressed, therefore possibly delaying full formation of the central nervous
system. 33
Clinical Research
The first case study relative to neuropsychological functioning is that of a
17-year-old adult male who received many different CS for a bout of ulcerative
colitis and who eventually developed steroid induced stupor (depression).34 He
was given hydrocortisone (HC) for two days at 100 mg q.Ld. While on the HC,
he experienced an anxiety attack. He was next given oral prednisone for six
days at 20 mg t.Ld. His ulcerative colitis symptoms exacerbated and he was
again put on HC at 100 mg q.Ld. This time while on HC, he became extremely
agitated and made a suicide attempt. The ulcerative colitis improved and his
medication was switched to ACTH at 40 units Lm. daily. This dosage was
decreased gradually over 10 days. After these 10 days, his bowel problems
were markedly improved but his psychological state had deteriorated and he
went into a catatonic stupor.
He was given neuroleptic medication, and over the next four weeks, his
stupor mildly improved while his psychomotor functioning only moderately
improved. He again became suicidal. Because of the ineffectiveness of the
neuroleptic medications, electroconvulsive therapy (ECT) was used. He
responded very well to a course of ECT comprised of five treatments. The
intensity of the symptoms in this patient was most likely precipitated by the high
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dose of CS that he was receiving and the fact that he was receiving them
intravenously. Medications injected intravenously are rapidly absorbed in the
bloodstream and remain more concentrated. His personal sensitivity to the CS
may also have been a factor. It was noted that family and personal history of
psychological problems was unremarkable.
Neuropsychological changes occur not only in adults but also in children.
Bender, Lerner, and Poland 31 studied the psychological functioning of 32
children, ages 8-16 years old (mean=14 years), who were currently hospitalized
for exacerbations of severe asthma. The children received burst therapy of oral
prednisone, a common CS, as well as inhaled CS and oral theophylline. Burst
CS therapy uses alternating high/low dosage days, with high dosages averaging
61.4 mg and low dosages averaging 6.97 mg. All subjects were evaluated at
high steroid and low steroid dose.
Psychological functions that were tested included hyperactivity, fine motor
control, mood, attention, impulsivity, and memory. Other areas assessed were
asthma severity, intelligence, socioeconomic status, and family functioning. All
testing was done while the child's asthma symptoms were stable. Three areas
of psychological functioning were found to significantly fluctuate between high
and low steroid dosage days, while the other areas were relatively unchanged.
All children reported higher anxiety levels during high versus low dose days.
Verbal memory scores were decreased and the children also scored higher on
the test for depression. Bender and associates31 found no factors that would
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indicate the above changes were from anything other than the steroids. In
addition, age, intelligence, socioeconomic status, and asthma severity did not
predict a child's susceptibility to neuropsychological difficulties. However,
impaired psychosocial functioning and family dysfunction were moderately
associated with mood and memory deterioration. This study showed how
dosage, patient susceptibility, and underlying personality may affect sensitivity to
CS.
Most studies dealing with neuropsychological functioning in patients
receiving corticosteroids report a decrease in CNS functioning. 3o,31,33,34 However,
Denburg, Denburg, and Carbotte 32 reported improvement in cognition, mood,
and/or systemic lupus erythematosus (SLE) symptom rating in ten women after
low doses of CS. The 10 women participating in the study had not received CS
for at least six months prior to this study. They completed three randomly
assigned drug/placebo pairings. Those receiving CS had 0.5 mg/kg of
prednisone daily. Analysis of variance (AN OVA) yielded "positive drug effects
for cognition, mood, and SLE symptom ratings.,,32(P1311) Despite the short time
this study was run, the authors feel that more research should be carried out in
this area because of positive CS effects on the patient living with SLE.
Therapeutic Intervention
In the review of the literature, one prophylactic medication was noted.3D
Lithium has been used prophylactically to decrease the neuropsychological side
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effects of CS in people with multiple sclerosis and retrobulbar neuritis. Mild to
moderate results have been achieved.
Precautions for the Physical Therapist
As physical therapists, you cannot alter the moods of your patient. But
being sensitive to changes in your patient's personality or mood is very
important if he/she is receiving CS. If intense personality and mood changes are
observed, the physician should be notified so possible adjustments in dose and
form of CS may be made.

CHAPTER VII
STEROID MYOPATHY
Steroid myopathy is a common adverse effect of corticosteroids. In the
literature, there are two forms of steroid myopathy.2.3.7.8.35-39 The two forms are
chronic steroid myopathy and acute necrotizing myopathy.
Chronic steroid myopathy presents with distinguishing
characteristics.2.7.8.35.38 The onset of muscle weakness is insidious, chronic, and
painless. Weakness is symmetrical and begins in the pelvic girdle, moving to
the shoulder girdle and then to the distal extremities. Type liB (fast twitch)
muscle fibers are the most often affected. Tests will reveal an elevated creatine
excretion in the urine which is an indicator of protein wasting of the muscles.
Although pain is not the main complaint, patients may complain of mild myalgia
and arthralgia.
Acute necrotizing steroid myopathy is associated with the use of
corticosteroids and neuromuscular blockades (NMBs). It most often occurs
when NMBs are used to paralyze the respiratory muscles of patients who are
suffering from status asthmaticus. NMBs allow easy intubation by paralyzing the
respiratory muscles that are in spasm. Intubation is necessary so the patient
can receive the proper ventilation he/she needs, by way of a respirator or
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mechanical ventilation. The severe nature of status asthmaticus often requires
that patients be maintained on both CS and NMBs for an extended period of
time. Acute necrotizing steroid myopathy is discovered when the use of NMBs
are discontinued. Acute nectrotizing steroid myopathy has also been associated
with the use of steroids alone.
Both etiologies of acute steroid myopathy are characterized by the
following signs and symptoms. 35,37,39 They both have an acute onset. Moderate
to severe flaccid weakness will develop and atrophy of the muscles will be
evident. In acute steroid myopathy, the distal extremities are the most severely
affected. High creatine excretion will also be noted. Electromyographic (EMG)
readings will give mixed results.
Both chronic and acute steroid myopathy are reversible with exercise and
dose reduction of both NMBs and CS. 2 Complete recovery may take from one to
four months or up to two years.2
Mechanism
The mechanisms leading to chronic or acute steroid myopathy can only
be hypothesized 2,7,35,36,38,40 One theory is that corticosteroids cause an
accelerated breakdown of muscle protein. 35 Skeletal muscle has many CS
receptors and is considered a "target" organ of CS. 2 The breakdown of muscle
protein may be induced by corticosteroids by "decreased uptake of amino acids
by skeletal muscle and inhibition of amino acid incorporation into proteins.,,2(p59)
It has also been theorized that when muscle is immobilized, either naturally or
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induced by NMBs, the number of corticosteroid receptors increase. 35 ,36,40 The
increased number of receptors causes the patient to become hypersensitive to
the deleterious effects of CS and accelerate muscle wasting.
The catabolic effects of CS are most pronounced in the muscles that are
the least active in protein synthesis. 2 When muscle is exercised on a regular
basis, it becomes more active in protein synthesis than when it is immobilized or
not exercised on a regular basis. This also supports the theory that immobilized
muscle will be more susceptible to myopathy. Therefore, if a person is on CS
and does not exercise regularly, he/she may be more at risk for steroid
myopathy. Because their muscles are not active in protein synthesis and
because they may contain more CS receptors, people who do not exercise
regularly are most affected by the catabolic effects of CS. Horber, Scheidegger,
GrOnig, and Frey40 concluded that exercise may reduce the effects of steroid
myopathy. Their study will be discussed in further detail later in this chapter.
Clinical Research
Askari, Vignos, and Moskowitz8 presented a case study of eight women
who developed chronic steroid myopathy while receiving high doses of
prednisone. They were receiving prednisone for various disease processes of
connective tissue: 1) polymyositis, 2) systemic lupus erythematosus (SLE),
3) rheumatoid arthritis (RA), and 4) shoulder hand syndrome (SHS). All of the
women experienced an insidious onset of weakness. In almost all of the women
muscle weakness was symmetrical and most pronounced in the pelvic girdle with
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less involvement at the shoulder girdle and distal musculature. Five of the
women reported diffuse myalgia. Creatine excretion was elevated in all the
women. The authors concluded that no correlation existed between the extent of
the myopathy and the cumulative dose of CS that the patient had received. All
the women recovered from this bout of steroid myopathy through dose reduction
of CS and an active exercise program. None of the women showed a relapse of
myopathy during the follow-up time of 120 to 360 days. As a point of interest, all
of the women had developed at least two or more of the other adverse effects of
CS, with osteoporosis being the most common.
Jennifer Grant2 adapted a functional classification system from this case
study (Table 1).38 This classification uses difficulty in functional activities to
determine the level of weakness. During Class I, or advanced level of
functioning, the patient only has difficulty in climbing stairs. In Class 2, or high
level of functioning, the patient cannot rise from a chair without assistance of
some kind. If patients cannot walk without assistance, they are classified as
Class 3, or intermediate level of functioning. In the final class, Class 4, or low
level of functioning, patients cannot elevate their eXtremities or move in bed.
Pangyres, Squier, Mills, and Newsom-Davis38 reported the case study of a
13-year-old Greek girl who developed acute steroid myopathy from steroids
alone. NMBs were not used in this case. The child was receiving CS for
myasthenia gravis. She had received a total dose of 5.48 grams of
methylprednisolone. Weakness was most evident distally. She was unable to
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Table 1.-Functional Classification of Muscle Weaknessa

Class

Level

Functional Capacity

1

Advanced

Has difficulty in climbing stairs

2

High

Cannot rise from chair

3

Intermediate

Cannot walk without assistance

4

Low

Cannot elevate extremities or move in bed

aFunctional classification categories are adapted from Askari A, Vingnos PJ,
Moskowitz RW. Steroid myopathy in connective tissue disease. Am J Med.
1976;61 :485-492 and Grant J. Corticosteroid side effects: implications for PT.
PT Mag Phys Ther. 1994;2:56-60.
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lift her legs from the bed. Her facial muscles were also affected and she had
difficulty swallowing and talking. Tendon reflexes were absent with the
exception of bilateral tricep jerks. EMG studies showed normal motor and
sensory conduction. The clinical features of this case did not appear to be from
the myasthenia gravis. Signs and symptoms of myasthenia gravis are 21 ptosis,
diplopia, and muscle fatigability. Ocular muscles are affected in 85% of the
cases. Deep tendon reflexes are normal. Because the signs and symptoms did
not fully correlate with myasthenia gravis, the authors felt that a large dose of CS
was the possible cause of the weakness. Myasthenia gravis at times blocks
transmission at the neuromuscular junction such as a neuromuscular blockade
works to immobilize the muscles. Therefore, the muscles are less active in
protein synthesis and become hypersensitive to the myopathic effects of CS, as
stated previously in this chapter. 38
A third form of steroid myopathy is that induced by a combination of CS
and NMBs. Steroids and NMBs may be used together when a patient goes into
status asthmaticus as described earlier. 9 ,35,36,39,41
A case study by Griffin and colleagues41 was carried out on a 29-year-old
man. He came to the emergency room with wheezes and signs of an upper
respiratory tract infection (URI). His past medical history was positive for steroid
dependent asthma. Because of his abnormal arterial blood gas (ABG) readings,
he was intubated immediately. Before intubation, NMBs were used to facilitate
the process. He remained on CS and NMBs for many days to aid with
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ventilation and proper air exchange. On day 16 of his hospitalization, all NMBs
and sedatives were discontinued but he remained on a ventilator. On
examination, after discontinuation of NMBs, flaccid quadriplegia existed. Deep
tendon reflexes were severely decreased but sensation was intact. Myoglobin
was detected in the urine, indicating muscle breakdown. He was weaned from
the respirator on day 31, and with the help of physical therapy, he was able to
ambulate independently after one month. The authors felt that this patient's
flaccid quadriplegia was due to the combination of steroids and NMBs as the
patient had full nutritional support all through his hospitalization, his electrolytes
were kept in balance, and he had no past medical history of a neuromuscular
disorder.
Hirano et al 35 presented a similar case study. An 18-year-old male was
admitted to the hospital because of a severe asthma attack. He was treated with
intravenous (IV) methylprednisone and paralyzed with vecuronium (a NMB)
before intubation and for the next 12 days. Following discontinuation of NMBs,
he had flaccid quadriplegia and had lost 10 kg of body weight. He remained on
the methylprednisone. He was mentally alert and cranial nerves were intact.
Sensation was normal and deep tendon reflexes were present. Nerve
conduction studies were unremarkable. On day 42 he was extubated, his
methylprednisone was decreased and he began to improve. On day 68 he was
able to walk short distances in the parallel bars. Because of the lack of
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neurogenic changes, the authors believed that the flaccid quadriplegia was due
to a combination of CS and NMBs.
Therapeutic Intervention
Three options exist to lessen the effects of steroid myopathy. The first
option is either discontinuing the CS or decreasing the dosage. 7 •8 The second
option is changing the medication to another steroid derivative. 8 The last option
is to institute an active exercise program for those who receive corticosteroids.
Horber, Scheidegger, GrOnig, and Frey40 concluded that myopathy can be
reversed by active exercise. "The purpose of their research was 1) to quantify
the decreases in thigh muscle strength in patients with prednisone and 2) to
establish whether the thigh muscle area can be increased and its function
improved by training."(p83) The study included 24 subjects (12 experimental and
12 control subjects). The 12 in the experimental group were all at least six
months status post renal transplantation and were receiving 12.6 ± 3.3 mg/day of
prednisone. The 12 control subjects were not currently partiCipating in any
physical training or receiving CS. A Cybex II was used to assess muscle
strength and power. Isokinetic tests were done on five occasions; specifically, on
two different days before training, on day 35 of training, and on two days post
training. The 12 experimental subjects trained isokinetically on the Cybex II
three times per week for 50 days. To determine thigh muscle area and density,
computerized tomography (CT) of the thigh was done. As compared to the
control group, before instituting training, the experimental group had 1) a higher
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fat to muscle ratio, 2) a lower mean torque, and 3) a decreased total work output.
At the end of training, the two groups were equal in the three tested areas. This
suggests that active exercise may offset the adverse effects of prednisone.
Precautions for the Physical Therapist
It is important for the physical therapist to differentiate between chronic
and acute steroid myopathy. The signs and symptoms of each of the
myopathies were presented in the introduction to this chapter. One red flag for
the physical therapist is to note any increase in creatine excretion (above the
normal) in the urine, which indicates protein catabolism. This seems to be an
accurate indicator of even mild myopathy.2
With an active exercise program the patient will improve. However, return
of strength may be fast or slow. Complete recovery may be as quick as one to
four months or it may take up to one or two years.
Treatment of the patient should include active exercise and functional
activities. 2,40 Sample exercises to correlate with Askari's functional
classifications were given by Jennifer Grant,2 MS, PT. They have been reprinted
in Table 2. Goals of treatment should be to increase strength, regain
endurance, and teach energy conservation techniques. Assistive devices may
be needed for some patients. Proper home instructions and referral to a
physician should be made.

35

Table 2.-Sample Exercise Prescription Based on Functional Statusa

Low Level

Intermediate Level

High Level

Advanced Level

Toe raises in
standing position

Bench step

Gravity eliminated Assisted bridging

Bridging

One-leg
bridging

Against gravity

Semi-squats with
upper extremity
support

Squats with
extremity support

Lunges

Chair pushups

Half kneel to
standing position

Active range of
motion (AROM)

Light resistive
exercise against
gravity

aReprinted with permission. Grant J. Corticosteroid side effects: implications
for PT. PT Mag Phys Ther. 1994;2:56-60.

CHAPTER VIII
CONCLUSION
This project discussed a few of the possible adverse effects of CS use
and their implications for the physical therapist. A physical therapist cannot
decide whether or not a patient should be on CS. However, he/she should be
aware of the signs and symptoms of the possible adverse effects from the use of
these medications which may be apparent during evaluation and/or assessment.
Being aware of the medication complications will allow the therapist to
make the appropriate clinical decision and provide quality care to that patient.
The therapist may have to alter how he/she conducts the evaluation. When
planning the treatment and progression of a patient, the therapist must also take
into consideration the secondary effects of CS, whether it be osteoporosis, a
compromised immune system, GI complications, avascular necrosis,
neuropsychological difficulties, or steroid myopathy.
It is also the duty of the physical therapist to inform the physician of any
observed changes in the patient's functioning, such as a decrease in the
proximal strength of the lower extremities and a decrease in general endurance.
A therapist will know how to treat steroid myopathy, but the physician may also
be able to decrease the dosage of CS or switch the patient to another form of
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CS. The therapist and physician together can help the patient maintain his/her
highest level of function.
The adverse effects discussed mayor may not affect a patient receiving
CS. Throughout the literature it seems apparent that the adverse effects are
very patient specific. Patient susceptibility to CS may playa significant role in
whether or not he/she will develop any of the adverse effects and to what extent
they will affect the patient.
Although CS are therapeutic agents, one question remains. Do the
benefits of CS in treating the primary diagnosis outweigh the risks and
consequences of the adverse effects? It is a Catch 22. On one hand, the
primary diagnosis may be exacerbated without the use of corticosteroids, but on
the other hand, the adverse effects of CS may be debilitating. But in most
cases, the benefits of CS outweigh the potential adverse effects.

APPENDIXA
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